Abstract 100P
Background
Colon cancer (CC) is one of the most common malignancies in the world. In this study, we investigated the involvement of a mitosis related chromosome condensation protein NCAPG in tumor progression, and in the prognosis of human CC.
Methods
The patient cohort in this study consisted of 123 CC cases from 2009 to 2013, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the NCAPG expression in 123 pairs of normal and CC tissues and 7 colon cells. Based on the expression of NCAPG, one CC cell with high NCAPG level was chosen for knockdown of NCAPG expression. The effect of NCAPG knockdown on the growth, migration and invasion of NCAPG-manipulated CC cells was examined.
Results
NCAPG protein overexpression was observed in 88 patients and was significantly correlated with depth of invasion, distant metastasis, staging, and poor disease-free and overall survival. Multivariate Cox regression analysis showed that NCAPG overexpression is an indenpendent prognostic marker for CC. Furthermore, NCAPG expression was elevated in several CC cells. In vitro experiments indicated that NCAPG knockdown inhibited CC cell growth, migration and invasion.
Conclusions
This study suggests that overexpression of NCAPG can be a useful marker for predicting the outcome of CC patients and that NCAPG targeting can represent a potential modality for treating CC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chi Mei Medical Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract